Skip to main content
Premium Trial:

Request an Annual Quote

Hologic Completes Acquisition of Gen-Probe

NEW YORK (GenomeWeb News) – Hologic has completed its $3.8 billion acquisition of Gen-Probe following approval from Gen-Probe's shareholders yesterday.

Gen-Probe will now become a wholly owned subsidiary of Hologic. Carl Hull, the chairman and CEO of Gen-Probe, will stay with Hologic for at least 15 months to direct the combined diagnostic operations, as the firms previously announced.

Hologic signed the agreement in April to acquire Gen-Probe for $82.75 per share. The firm reiterated today that it expects the deal to be $.20 accretive to its non-GAAP adjusted earnings per share in fiscal 2013. It also said that the combined firm expects to realize around $75 million in cost synergies within three years following closure of the transaction.

As of today, Gen-Probe's shares have ceased trading on the Nasdaq.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.